Sovereign wealth funds are dialing up their direct exposure to technology and healthcare start-ups, but this trend is accompanied by a varied collection of co-investment models
The sovereign wealth funds of China and Russia make for odd yet strangely complementary bedfellows. China Investment Corporation (CIC) was established to diversify some of the country’s foreign exchange...
China-based data storage software services provider XSKY has raised a RMB320 million ($45 million) Series D led by China's State Owned Capital Venture Capital Fund.
CF PharmTech, a Chinese medical devices maker focused on innovative respiratory products, has raised a $50 million Series F round with support from CICC Capital.
Chinese insulin manufacturer Gan & Lee Pharmaceuticals, which counts Qiming Venture Partners and Goldman Sachs among its investors, raised RMB2.5 billion ($354 million) through an A-share IPO.
KKR has agreed to buy a 54% stake in Indian drug maker J.B. Chemicals & Pharmaceuticals for INR31.1 billion ($416 million) and made an open offer for an additional 26% of the company.